Phage display peptide probes for imaging early response to bevacizumab treatment

Amino Acids

Volumn 41, Issue 5, 2011, Pages 1103-1112

  Cao, Qizhen ^a   Liu, Shuanglong ^a   Niu, Gang ^b   Chen, Kai ^b   Yan, Yongjun ^b   Liu, Zhaofei ^a   Chen, Xiaoyuan ^a,b  

^a STANFORD UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

Author keywords

Angiogenesis; Bevacizumab; Molecular imaging; Phage display; Therapy response

Indexed keywords

BEVACIZUMAB; BEVACIZUMAB RESPONSIVE PEPTIDE; FLUORODEOXYGLUCOSE F 18; PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; DRUG TARGETING; EX VIVO STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VIVO STUDY; MOLECULAR IMAGING; MOLECULAR PROBE; MOUSE; NONHUMAN; PHAGE DISPLAY; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; TUMOR VASCULARIZATION; TUMOR VOLUME;

AMINO ACID SEQUENCE; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DRUG MONITORING; FEMALE; HUMANS; MICE; MICE, NUDE; MOLECULAR PROBES; MOLECULAR SEQUENCE DATA; PEPTIDE LIBRARY; PEPTIDES; POSITRON-EMISSION TOMOGRAPHY;

EID: 81255196236     PISSN: 09394451     EISSN: 14382199     Source Type: Journal    
DOI: 10.1007/s00726-010-0548-9     Document Type: Article

References (38)

1. Arap W, Pasqualini R, Ruoslahti E (1998) Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279:377-380 (Pubitemid 28063372)
2. Augustin HG, Kozian DH, Johnson RC (1994) Differentiation of endothelial cells: analysis of the constitutive and activated endothelial cell phenotypes. Bioessays 16:901-906 (Pubitemid 24974469)
3. Atkinson AJ, Colburn WA, DeGruttola VG, DeMets DL, Downing GJ, Hoth DF, Oates JA, Peck CC, Schooley RT, Spilker RA, Woodcock J, Zeger SL (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89-95 (Pubitemid 32225406)
4. Borsum T, Hagen I, Henriksen T, Carlander B (1982) Alterations in the protein composition and surface structure of human endothelial cells during growth in primary culture. Atherosclerosis 44:367-378 (Pubitemid 12029368)
5. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878-1886 (Pubitemid 30207647)
6. Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581-611 (Pubitemid 39099316)
7. Fox WD, Higgins B, Maiese KM, Drobnjak M, Cordon-Cardo C, Scher HI, Agus DB (2002) Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. Clin Cancer Res 8:3226-3231 (Pubitemid 35155035)
8. Fujio Y, Walsh K (1999) Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchoragedependent manner. J Biol Chem 274:16349-16354
9. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME (2001) A tabulated summary of the FDG PET literature. J Nucl Med 42:1S-93S (Pubitemid 32423895)
10. Hallahan D, Geng L, Qu S, Scarfone C, Giorgio T, Donnelly E, Gao X, Clanton J (2003) Integrin-mediated targeting of drug delivery to irradiated tumor blood vessels. Cancer Cell 3:63-74 (Pubitemid 37443891)
11. Han Z, Fu A, Wang H, Diaz R, Geng L, Onishko H, Hallahan DE (2008) Noninvasive assessment of cancer response to therapy. Nat Med 14:343-349 (Pubitemid 351347907)
12. Hardy B, Raiter A, Weiss C, Kaplan B, Tenenbaum A, Battler A (2007) Angiogenesis induced by novel peptides selected from a phage display library by screening human vascular endothelial cells under different physiological conditions. Peptides 28:691-701 (Pubitemid 46205004)
13. Hlatky L, Hahnfeldt P, Folkman J (2002) Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 94:883-893 (Pubitemid 34778087)
14. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD, Wiegand SJ (1999) Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284:1994-1998 (Pubitemid 29309448)
15. Hsu AR, Hou LC, Veeravagu A, Greve JM, Vogel H, Tse V, Chen X (2006) In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in an orthotopic glioblastoma model. Mol Imaging Biol 8:315-323 (Pubitemid 44741368)
16. Hu L, Hofmann J, Zaloudek C, Ferrara N, Hamilton T, Jaffe RB (2002) Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol 161:1917-1924 (Pubitemid 35265548)
17. Hughes MS, Marsh JN, Zhang H, Woodson AK, Allen JS, Lacy EK, Carradine C, Lanza GM, Wickline SA (2006) Characterization of digital waveforms using thermodynamic analogs: detection of contrast-targeted tissue in vivo. IEEE Trans Ultrason Ferroelectr Freq Control 53:1609-1616 (Pubitemid 44335169)
18. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342 (Pubitemid 38702844)
19. Jaffe CC (2006) Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol 24:3245-3251 (Pubitemid 46622065)
20. Jain RK (1998) The next frontier of molecular medicine: delivery of therapeutics. Nat Med 4:655-657 (Pubitemid 28274655)
21. Jain RK (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7:987-989 (Pubitemid 32937367)
22. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58-62 (Pubitemid 40093472)
23. Jain RK, Duda DG, Clark JW, Loeffler JS (2006) Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3:24-40 (Pubitemid 43108832)
24. Kelly KA, Waterman P, Weissleder R (2006) In vivo imaging of molecularly targeted phage. Neoplasia 8:1011-1018 (Pubitemid 44936150)
25. Kerbel RS (2006) Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 312:1171-1175 (Pubitemid 43801134)
26. Li ZB, Wu Z, Chen K, Ryu EK, Chen X (2008) 18F-labeled BBNRGD heterodimer for prostate cancer imaging. J Nucl Med 49:453-461 (Pubitemid 351355212)
27. Liu Z, Yan Y, Chin FT, Wang F, Chen X (2009) Dual integrin and gastrin-releasing peptide receptor targeted tumor imaging using (18)F-labeled PEGylated RGD-bombesin heterodimer (18)F-FBPEG( 3)-Glu-RGD-BBN. J Med Chem 52:425-432
28. Miller KD, Soule SE, Calley C, Emerson RE, Hutchins GD, Kopecky K, Badve S, Storniolo A, Goulet R, Sledge GW Jr (2005) Randomized phase II trial of the anti-angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory. Breast Cancer Res Treat 89:187-197 (Pubitemid 40249053)
29. Padhani AR (2003) MRI for assessing antivascular cancer treatments. Br J Radiol 76(Spec No. 1):S60-S80 (Pubitemid 39530317)
30. Pasqualini R, Ruoslahti E (1996) Organ targeting in vivo using phage display peptide libraries. Nature 380:364-366 (Pubitemid 26097120)
31. Rajotte D, Arap W, Hagedorn M, Koivunen E, Pasqualini R, Ruoslahti E (1998) Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J Clin Invest 102:430-437 (Pubitemid 28335203)
32. Seung-Min L, Gil-Suk Y, Eun-Sang Y, Tae-Gyun K, In-San K, Byung- Heon L (2009) Application of phage display to discovery of tumorspecific homing peptides: developing strategies for therapy and molecular imaging of cancer. Methods Mol Biol 512:355-363
33. Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J, Sledge GW Jr (2001) The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 61:3369-3372 (Pubitemid 32695027)
34. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK (2004) Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64:3731-3736 (Pubitemid 38697278)
35. Tozer GM (2003) Measuring tumour vascular response to antivascular and antiangiogenic drugs. Br J Radiol 76(Spec No. 1):S23-S35 (Pubitemid 39530313)
36. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145-147 (Pubitemid 38524883)
37. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E, Munn LL, Jain RK (2004) Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6:553-563 (Pubitemid 40017699)
38. Wu Y, Cai W, Chen X (2006) Near-infrared fluorescence imaging of tumor integrin alpha v beta 3 expression with Cy7-labeled RGD multimers. Mol Imaging Biol 8:226-236 (Pubitemid 44193419)